News Column

Data on Nanotechnology Reported by Researchers at Seoul National University (Versatile RNA Interference Nanoplatform for Systemic Delivery of RNAs)

July 2, 2014



By a News Reporter-Staff News Editor at Biotech Week -- A new study on Nanotechnology is now available. According to news reporting originating from Seoul, South Korea, by NewsRx correspondents, research stated, "Development of nontoxic, tumor-targetable, and potent in vivo RNA delivery systems remains an arduous challenge for clinical application of RNAi therapeutics. Herein, we report a versatile RNAI nanoplatform based on tumor-targeted and pH-responsive nanoformulas (NFs)."

Our news editors obtained a quote from the research from Seoul National University, "The NF was engineered by combination of an artificial RNA receptor, Zn(II)-DPA, with a tumor-targetable and drug-loadable hyaluronic acid nanoparticle, which was further modified with a calcium phosphate (CaP) coating by in situ mineralization. The NF can encapsulate small-molecule drugs within its hydrophobic inner core and strongly secure various RNA molecules (siRNAs, miRNAs, and oligonucleotides) by utilizing Zn(II)-DPA and a robust CaP coating. We substantiated the versatility of the RNAi nanoplatform by demonstrating effective delivery of siRNA and miRNA for gene silencing or miRNA replacement into different human types of cancer cells in vitro and Into tumor-bearing mice in vivo by intravenous administration. The therapeutic potential of NFs coloaded with an anticancer drug doxorubicin (Dox) and multidrug resistance 1 gene target siRNA (siMDR) was also demonstrated in this study. NFs loaded with Dox and siMDR could successfully sensitize drug-resistant OVCAR8/ADR cells to Dox and suppress OVCAR8/ADR tumor cell proliferation in vitro and tumor growth in vivo."

According to the news editors, the research concluded: "This gene/drug delivery system appears to be a highly effective nonviral method to deliver chemo- and RNAi therapeutics into host cells."

For more information on this research see: Versatile RNA Interference Nanoplatform for Systemic Delivery of RNAs. ACS Nano, 2014;8(5):4559-4570. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)

The news editors report that additional information may be obtained by contacting K.Y. Choi, Seoul National University, Dept. of Chem, Seoul, South Korea. Additional authors for this research include O.F. Silvestre, X.L. Huang, K.H. Min, G.P. Howard, N. Hida, A.J. Jin, N. Carvajal, S.W. Lee, J.I. Hong and X.Y. Chen (see also Nanotechnology).

Keywords for this news article include: Asia, Seoul, South Korea, Nanotechnology

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters